logo-loader

Proteomics International Laboratories raises funds for diabetic kidney test

Published: 00:00 28 Dec 2016 GMT

shutterstock_263120237_5863199195242
Proteomics has raised funds.

The directors, who were scaled back in-line with other shareholders, have committed to top up their scale-back by buying shares in the open market.

It is worth noting that Proteomics has a tight free float, and directors buying on-market shows a vote of confidence.

The share purchase plan follows a placement to sophisticated investors, which raised $1.44 million.

The combined issues have raised $2 million, before costs.

The funds will be used to advance Proteomics’ activities in diagnostics and analytical services, specifically to support:

- the development and commercialisation of its flagship diagnostic product, PromarkerD, a breakthrough predictive test for diabetic kidney disease; and
- the rollout of Proteomics’ new analytical testing services for the fast-growing clinical trials market.

Recent clinical studies have shown that PromarkerD correctly predicts 61-97% of individuals who went on to have a clinically significant decline in kidney function within four years.

There are currently 415 million adults worldwide with diabetes, and about one-third of these people have chronic kidney disease which can lead to dialysis or kidney transplant.

Proteomics has multiple commercialisation pathways for PromarkerD - as a laboratory developed test (LDT), a standard clinical pathology in-vitro diagnostic test and a companion diagnostic (CDx).

In October, the company edged out shipbuilding giant Austal and Fortescue Metals Group to win the Western Australia Exporter of the Year Award.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

58 minutes ago